[1] GHAZALA R,EL-ATTAR E,ABOUZEID Z.Circulating miRNA 27a and miRNA150-5p; a noninvasive approach to endometrial carcinoma[J].Molecular Bio Rep,2021,2(10):4351-4360.
[2] 张明川,王莉. 调强放疗联合化疗对子宫内膜癌患者疗效和癌基因表达的影响[J].国际妇产科学杂志,2019,46(5):591-594.
[3] 周琦,吴小华,刘继红,等. 子宫内膜癌诊断与治疗指南(第四版)[J].中国实用妇科与产科杂志,2018,34(8):880-886.
[4] 杨学宁,吴一龙. 实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):25-30.
[5] 周琳,孟琼,杨铮,等. 基于FACT-Cx(V4.0)量表的宫颈癌患者生命质量影响因素分析[J].中华疾病控制杂志,2017,21(9):926-929.
[6] 游兴文,管华平,王艳虹,等. 放化疗联合应用对高危子宫内膜癌患者血清肿瘤标志物水平及预后的影响[J].癌症进展,2020,18(1):48-50.
[7] DEE E C,BYME J D,WOJ Y.Evolution of the role of radiotherapy for anal cancer[J].Cancers,2021,13(6):1208.
[8] CHRISTOPH S,DIRK J,MARKUS W B,et al. Chemotherapy for pancreatic cancer[J].Presse Med,2019,48(3 pt 2):e159-e174.
[9] 张果,索红燕,沈晓燕,等. 晚期子宫内膜癌序贯放化疗的初步研究[J].中华妇产科杂志. 2019,54(2):103-109.
[10] 李二建,黄伦,黄楚鑫,等. TC化疗联合放疗对高危子宫内膜癌术后疗效及安全性的Meta分析[J].中国计划生育和妇产科,2020,12(12):27-33.
[11] MWALE A,KATOWA M P,KALUSOPA V M,et al. Experiences with the use of vaginal dilator by cervical cancer women who received pelvic radiotherapy at cancer diseases hospital,lusaka zambia[J].Open J Obstet Gynecol,2021,11(10):1386-1396.
[12] MITACHI K,ARIAKE K,SHIMA H,et al. Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer[J].Sci Rep,2021,11(1):6541.
2022, Vol. 39 
